Biomark SSAT1 Assay

Etharums ser quidem rerum facilis dolores nemis omnis fugats vitaes nemo minima rerums unsers sadips amets.

BIOMARK SSAT1 ASSAY

BioMark’s initial assay detects SSAT1, an enzyme with elevated levels in numerous cancers, using an FDA approved drug. The assay targets a well researched and understood metabolic pathway. BioMark is amongst a unique group of companies that uses a safe therapeutic agent for diagnostic indication. This assay (SSAT1) can be used as a non-invasive, cost effective red alert tool for physicians globally.

BioMark has completed a comprehensive set of trial and is currently assembling a submission package to Health Canada for market approval for this test which physicians can use as a screening test for Lung and Breast Cancer and help to assess the need for more definitive imaging or other molecular test.

There is compelling scientific evidence to suggest that the SSAT1 Assay can be expanded for Glioblastoma (GBM), Gastrointestinal, Prostate and Head and Neck Cancers.

physician-in-digital-environment

CLINICAL APPLICATIONS

  • Test as a “Red Alert”
  • Measure response to treatment
  • Monitor for recurrence for cancer survivors

CLINICAL TRIALS COMPLETED OR IN PROGRESS

Urinary Excretion of Acetylamantadine by Cancer Patients
Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba
Status: Open. In the process of final submission to Health Canada

Urinary Excretion of Acetylamantadine by Cancer Patients in Bangladesh
Principal Investigator: Prof. (Dr.) Parveen Shahida Akhtar, Head of the Department, Medical oncology,National Institute of Cancer Research and Hospital, Dhaka, Bangladesh
Status: Completed.

Food Effects on the Pharmacokinetics of Amantadine
Principal Investigator: Prof. Zeneng Cheng, Hunan Tiger-xiangya Drug Evaluation center, China
Status: Completed.

Urinary Excretion of Acetylamantadine by Normal Healthy Volunteers
Principal Investigator: Dr. Bram Ramjiawan, Ph. D, St. Boniface Hospital and Research Centre
Status: Completed.

Spermidine/spermine N-acetyltransferase 1 (SSAT 1) Gene Expression in Human Cancer
Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba
Status: Open.

Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a Chemotherapy Regimen
Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba
Co-Investigator: Dr. Daniel S. Sitar, Ph.D, University of Manitoba
Co-Investigator: Dr. Paramjit Tappia, Ph.D, Asper Clinical Research Institute
Status: Open. Mid point assessment to establish proof of concept and patients still being enrolled
extended ethics approval